Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Kiniksa Pharmaceuticals International, plc

Get SEC filing alerts via email and in your feed for Kiniksa Pharmaceuticals International, plc

KNSA

Kiniksa Pharmaceuticals International, plc

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals develops and commercializes biologic therapies targeting inflammatory and autoimmune diseases, primarily focusing on cardiovascular conditions like recurrent pericarditis. Its portfolio includes ARCALYST, an IL-1 cytokine trap, and investigational monoclonal antibodies such as KPL-387 and KPL-1161. The company partners globally, leveraging licensing, out-licensing, and strategic collaborations to advance innovative treatments for unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Kiniksa Pharmaceuticals International, plc

1
1
Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals Reports 55.5% Revenue Growth to $214.3 Million in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals Reports 62% Revenue Growth to $677.6 Million for ARCALYST in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals Reports 61.2% Revenue Increase to $180.9 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals Reports 44% Revenue Growth to $156.8 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals Reports 72% Revenue Growth to $137.8 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals Reports 74% Increase in Product Revenue, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments